Denmark's Novo Nordisk has a stronger development pipeline of new drug candidates than it has ever had before, and thinks it can keep delivering the strong sales growth of the past decade, its chief executive said on Tuesday. The company, which is the world's largest insulin producer, has grown sales by 13 percent on average for the last 10 years, and it aims to increase its numbers of patients to 40 million in 2020 from 23 million in 2012. Novo has no long-term sales target, but it has a target for its operating profit to grow by 15 percent per year.
Help employers find you! Check out all the jobs and post your resume.
